Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Gilead Sciences' Yeztugo, a twice-yearly HIV prevention injection launched in June, is seeing rising use, but uptake is uneven. Health providers say some patients are not interested in the new option and others face insurance coverage gaps. The article points to early commercialization progress with adoption and reimbursement headwinds rather than a major financial surprise.

Analysis

Gilead Sciences' Yeztugo, a twice-yearly HIV prevention injection launched in June, is seeing rising use, but uptake is uneven. Health providers say some patients are not interested in the new option and others face insurance coverage gaps. The article points to early commercialization progress with adoption and reimbursement headwinds rather than a major financial surprise.